Citadel Advisors’s T2 Biosystems, Inc TTOO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
Sell
-943
Closed -$20.8K 15519
2023
Q3
$20.8K Buy
943
+787
+504% +$20.5K ﹤0.01% 12601
2023
Q2
$1.1K Sell
156
-147
-49% -$3.38K ﹤0.01% 13986
2023
Q1
$13.9K Buy
+303
New +$33.1K ﹤0.01% 13333
2022
Q4
Sell
-18
Closed -$10K 15627
2022
Q3
$10K Sell
18
-8
-31% -$5.26K ﹤0.01% 12283
2022
Q2
$21K Sell
26
-11
-30% -$16.3K ﹤0.01% 12395
2022
Q1
$97K Buy
37
+2
+6% +$4.25K ﹤0.01% 12317
2021
Q4
$90K Buy
35
+7
+25% +$24.3K ﹤0.01% 12821
2021
Q3
$126K Sell
28
-3
-10% -$15.1K ﹤0.01% 12589
2021
Q2
$185K Buy
31
+1
+3% +$6.46K ﹤0.01% 12250
2021
Q1
$244K Buy
30
+4
+15% +$42.4K ﹤0.01% 11297
2020
Q4
$164K Buy
+26
New +$159K ﹤0.01% 9887
2020
Q3
Sell
-14
Closed -$91K 10918
2020
Q2
$91K Buy
14
+12
+600% +$51K ﹤0.01% 9045
2020
Q1
$7K Sell
2
-3
-60% -$12.5K ﹤0.01% 9463
2019
Q4
$28K Sell
5
-1
-17% -$9.45K ﹤0.01% 8886
2019
Q3
$76K Buy
+6
New +$48.2K ﹤0.01% 8596
2019
Q2
Sell
-8
Closed -$101K 10016
2019
Q1
$101K Hold
8
﹤0.01% 8554
2018
Q4
$123K Sell
8
-6
-43% -$141K ﹤0.01% 8158
2018
Q3
$503K Buy
14
+3
+27% +$98.8K ﹤0.01% 6682
2018
Q2
$440K Buy
+11
New +$417K ﹤0.01% 6582

Other funds holding TTOO

Citadel Advisors's TTOO Position: Q4 2023 in Review

Citadel Advisors sold out of T2 Biosystems, Inc (TTOO) in Q4 2023, closing a stake of 10 shares — an estimated $221 sold.

Citadel Advisors first reported a position in TTOO in Q4 2015 and held it in 18 quarters. The position peaked at $434K in Q1 2021. 21 funds tracked by Wall St. Rank hold TTOO as of Q4 2023.

  • Citadel Advisors reported no remaining T2 Biosystems, Inc position as of Q4 2023 after selling out during the quarter.
  • Citadel Advisors sold 10 T2 Biosystems, Inc shares in Q4 2023, an estimated $221.
  • Citadel Advisors first reported a position in T2 Biosystems, Inc in Q4 2015 and held it in 18 quarters.
  • Citadel Advisors's T2 Biosystems, Inc position peaked at $434K in Q1 2021.
  • 21 funds tracked by Wall St. Rank held T2 Biosystems, Inc as of Q4 2023.

Based on Citadel Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.